Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study Assessing the Safety and Pharmacokinetics of Multiple Doses of AT-527 in Healthy Subjects

X
Trial Profile

A Phase I Study Assessing the Safety and Pharmacokinetics of Multiple Doses of AT-527 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir (Primary)
  • Indications COVID 2019 infections; Hepatitis C
  • Focus Adverse reactions
  • Sponsors Atea Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2023 According to Atea media release, company announced the presentation of new phase I, in vitro and in vivo data that demonstrate key profile attributes of bemnifosbuvir in treatment of COVID-19 and Hepatitis C. These results will be presented at the 36th International Conference on Antiviral Research (ICAR 2023) taking place from 13th-17th March 2023 at Lyon, France.
    • 23 Feb 2022 Status changed from recruiting to completed.
    • 29 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top